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ABSTRACT
Objective: The main aim of the present study was to investigate the levels of lipid and lipoproteins in causing secondary microvascular complications 
in diabetic patients. Patients of Type II diabetes mellitus are highly susceptible to various complications due to long-term persistence of hyperglycemic 
state in the body. Thus, it is imperative to study the effect of hyperglycemia on lipids as their subsequent oxidation can lead to complications such as 
nephropathy, neuropathy, and retinopathy in diabetics which can further lead to macrovascular complications in the body.
Methods: The diabetic patients were divided into two groups, based on the presence/absence of secondary microvascular complications, namely, 
nephropathy, retinopathy, and neuropathy. Two types of cases were included in the study, on the basis of duration, namely, 0–5 years and 5–10 years 
duration. Blood samples were collected and levels of hemoglobin and glycated hemoglobin were determined. The biochemical parameters, namely, 
random blood sugar, cholesterol, triglycerides, high-density lipoproteins, low-density lipoproteins (LDLs), and very LDLs were estimated.
Results: The lipid levels altered in diabetic patients, leading to the dyslipidemia and the cumulative effect of hyperglycemia and dyslipidemia leads to 
the oxidative stress in the body. The increased oxidation of lipids may lead to the occurrence of microvascular complications in the body. Furthermore, 
dyslipidemia has been found more prevalent in males as compared to females.
Conclusion: Due to the increased prevalence of diabetes in India, funding of this study would suggest that there is a need to accelerate the importance 
of monitoring lipid levels in diabetes. Diabetic patients should routinely monitor their glycemic status, renal, and lipid profile to avert microvascular 
complications associated with diabetes mellitus.
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INTRODUCTION
Diabetes mellitus is a chronic metabolic disorder characterized by 
hyperglycemia (elevated levels of blood glucose), develops due to 
the defects in insulin secretion, insulin action, or both [1]. According 
to diabetes atlas, the global prevalence of diabetes is estimated at 
415 million (8.8%) and predicted to rise to 642 million in the next 
25 years. In India, there are about 70 million people with diabetes 
and are expected to cross 124 million by 2040 [2]. Chronicity of 
hyperglycemia is associated with long-term damage and failure of 
various organ systems mainly affecting the eyes, nerves, kidneys, and 
the heart [3]. Various disorders such as obesity, insulin resistance, 
glucose intolerance, hypertension, and dyslipidemia lead to metabolic 
syndrome, responsible for the development of morbid and comorbid 
conditions [4]. The injurious effects of hyperglycemia are categorized 
into macrovascular complications (coronary artery disease, peripheral 
arterial disease, and stroke) and microvascular complications (diabetic 
nephropathy, neuropathy, and retinopathy). Endothelial dysfunction 
is an early event involved in pathogenesis of vascular complications 
in Type II diabetes mellitus patients who have insulin resistance and 
usually relative (rather than absolute) insulin deficiency [5].
Diabetes induces oxidative stress in the body which could dearrange 
various metabolisms [6]. High glucose levels increase the flux of 
sugar molecules through the polyol pathway, which causes sorbitol 
accumulation in cells. Moreover, this leads to the osmotic stress and it 
has been postulated as an underlying mechanism in the development 
of diabetic microvascular complications. These microvascular 
complications of diabetes depend on both the duration and the severity 
of hyperglycemia. High glucose concentrations can promote the non-
enzymatic formation of advanced glycosylated end products [7]. The 
hyperglycemia promotes the formation of reactive oxygen species 
(ROS), which interacts with both deoxyribonucleic acid (DNA) and 
proteins, causing cellular damage, especially targeting mitochondrial 
DNA. A study on the human retinal endothelial cell demonstrated 
very early mitochondrial DNA damage with hyperglycemia-induced 
overproduction of ROS [8]. ROS-mediated cellular damage may be a 
form of pathologic “memory” in the microvasculature that persists even 
after glucose normalization.
The prevalence of diabetes has been increasing at an alarming rate, thus 
it is imperative to understand the relationship between diabetes and 
its secondary complications. Approximately 193 million diabetics in the 
world remain undiagnosed predisposing them to the development of 
several long-term complications of untreated chronic hyperglycemia. 
Although intensive glycemic control lowers the incidence and 
progression of microvascular complications, the morbidity associated 
with these complications is still increasing. Patients with microvascular 
complications appear particularly prone to accelerated atherosclerosis 
and premature death. The presence of microvascular disease is also a 
predictor of coronary heart events [9].
The Indians are more prone to diabetes whether they may be residing in 
India or outside due to the certain characteristics. Approximately 25% of 
the people with new detected diabetes already have microvascular disease, 
suggesting that they have had the disease for 4–7 years by the time of the 
diagnosis. Hence, in a patient with diabetes, it is important to consider the 
treatment of other conditions and complications when present, as they 
are likely to result in poor quality of life and adverse outcome.
METHODS
Type II diabetic patients who visit the outpatient departments of the 
Dr. Rohit Kapoor Clinic and Civil Hospital, Amritsar, and 30 healthy 
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individuals, who came for routine checkup, considered as controls, 
were included in the study. The diabetic patients were divided into two 
groups, based on the presence/absence of secondary microvascular 
complications, namely, nephropathy, retinopathy, and neuropathy. 
Two types of cases were included in the study, on the basis of 
duration, namely, 0–5 years and 5–10 years duration (Table 1). This 
was confirmed by the patient’s medical history procured from the 
hospital. Group-wise distribution of subjects understudy included 
Group 1: 30 healthy controls, Group 2: 40 diabetic subjects without 
microvascular complications, and Group 3: 40 diabetic subjects with 
microvascular complications. Inclusion criteria involve diabetic 
males and females, with or without complication, in the age frame of 
30–70 years. Exclusion criteria included patients with hypothyroidism 
or hyperthyroidism, cardiac failure, renal failure, eye disorders before 
the onset of diabetes, and pregnant women. The study protocol was 
approved by the institutional ethical committee. Blood samples were 
collected from a prominent vein and level of hemoglobin (Hb) was 
estimated by Sahli’s [10]. The biochemical parameters were estimated 
using beacon diagnostics and Erba diagnostic kits. The blood sugar level 
was estimated spectrophotometrically at 505 nm by glucose oxidase-
peroxidase (POD) method [11]. Glycated Hb (HbA1C) level was estimated 
by ion exchange resin method using a commercially available kit (ERBA 
Diagnostics Mannheim GmbH, Mannheim/Germany) [12]. The serum 
cholesterol level was estimated spectrophotometrically at 505 nm by 
cholesterol oxidase-POD aminophenazone (CHOD-PAP) method [13]. 
The serum triglyceride level was estimated spectrophotometrically at 
505 nm by glycerol phosphate oxidase/POD method [14]. The serum 
high-density lipoproteins (HDLs) cholesterol level was estimated by 
CHOD-PAP after precipitating with phosphotungstic acid method. Very 
low-density lipoprotein (VLDL) cholesterol and LDL were calculated 
from Friedewald formula.
RESULTS AND DISCUSSION
The study included a total of 120 samples collected from healthy 
controls, diabetic patients with microvascular complications, and 
diabetic patients without microvascular complications. The blood 
samples were collected in aseptic conditions and renal profile, lipid 
profile, HbA1C, random blood sugar, and hemoglobin were estimated in 
each patient.
The mean age of patients involved in the present study was 45–60 years. 
The weight of patients involved in the study was determined and was 
found comparative to each other (Table 2). The level of hemoglobin was 
Table 1: Description of subjects understudy
Total population (n=110)
Healthy control (n=40) Diabetic patients without microvascular 
complications (n=40)






Females (n=20) Males (n=20) Females (n=20) Males (n=20)
- - 0–5 (years) 5–10 (years) 0–5 (years) 5–10 (years) 0–5 (years) 5–10 (years) 0–5 (years) 5–10 (years)
- - n=10 n=10 n=10 n=10 n=10 n=10 n=10 n=10
Table 2: Mean age and weight of diabetic patients with or without microvascular complications




Age (years) Weight (kg) Age Weight
Females Males
Healthy controls (I) 20 45.52±13.9 65.66±9.36 54.1±12.17 74.3±2.79
Diabetic patients without 
microvascular complications (II)
0–5 10 43.4±9.90 69±11.57 45.4±10.02 75.5±7.44
5–10 10 54.54±10.57 60.4±4.50 52.12±9.82 78.26±8.92














*Data are represented as mean±standard deviation
Table 3: Hemoglobin and HbA1C and diabetic patients with or without microvascular complications




Hb (g/dl) HbA1C (g/dl) Hb (g/dl) HbA1C (g/dl)
Females Males
Healthy control (I) 20 10.84±1.3 4.11±1.01 13.03±1.36 4.6±1.04
Diabetic patients without 
microvascular complications (II)
0–5 10 10.8±1.11 7.17±0.90 12.37±1.07 8.16±1.31
5–10 10 10.30±0.96 7.65±0.90 11.86±0.98 7.23±1.19














*Data are represented as mean±standard deviation. HbA1C: Glycated hemoglobin, Hb: Hemoglobin
Table 4: RBS in diabetic patients with or without microvascular complications
Group Duration of diabetes (years) Number of patients (n) RBS (mg/dl) RBS (mg/dl)
Healthy control (I) 10 94.23±16.83 109.9±16.35
Diabetic patients without 
microvascular complications (II)
0–5 10 94.23±16.83 223.3±25.89
5–10 10 204.4±37.43 216.25±33.30










*Data are represented as mean±standard deviation. RBS: Random blood sugar
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found higher in male patients as compared to female patients but was 
lower as compared to healthy controls.
HbA1C was found higher in diabetic patients as compared to controls 
(Table 3). Both male and female patients with microvascular 
complications had higher level of HbA1C as compared to patients 
without microvascular complications with the increase in the duration 
of disease; HbA1C levels have significantly increased, irrespective of 
gender differences. It can be inferred that the advanced glycation end 
products accumulated progressively in the tissues and organs. These 
products interfere with the normal functioning of organs and caused 
secondary complications of diabetes mellitus [15]. HbA1C is a significant 
biochemical marker in the prediction of microvascular complications in 
diabetic patients. Several studies showed the significant elevation in the 
level of glycated hemoglobin in blood serum of diabetic patients [16]. 
HbA1C also plays a significant role in the prediction of macrovascular 
complications as well [17].
In diabetic patients, hyperglycemic conditions arise due to non-
utilization of glucose by body cells due to insulin resistance shown 
by the cells or due to insulin deficiency [18]. This can result in the 
abnormalities of carbohydrate, protein, and fat metabolism. Diabetic 
patients have poor glycemic control which ultimately increases the risk 
for secondary problems due to the persistent hyperglycemic condition 
in the body. In the present study, both male and female diabetic patients 
revealed higher level of random blood sugar irrespective of the presence 
or absence of complication (Table 4).
Diabetic patients with microvascular complications have high 
(173.2±25.74) level of cholesterol among all the studied groups. It has 
also been observed that cholesterol levels did not reveal any significant 
increase with the duration of disease. Females were found to have 
higher cholesterol levels as compared to male patients (Table 5).
Triglycerides also followed the same pattern. Healthy controls showed 
normal triglycerides levels in both the genders. However, the levels 
were higher in diabetic patients. Maximum triglyceride level was found 
to be 192.34±34.36 mg/dl and 188±32.58 mg/dl in female and male 
diabetic patients, respectively, with microvascular complications with 
5 years of disease duration. HDL level did not show any significant 
differences among all the studied groups. Maximum level of HDL 
(45.33±12.82 mg/dl) and (43.7±1.77) was found in female and male 
healthy controls, respectively. LDL levels were higher in male diabetic 
patients with increased disease duration as compared to their female 
counterparts (Table 6). Insulin resistance leads to the increased 
susceptibility of LDL to oxidation, leading to impaired glucose tolerance. 
Increased LDL cholesterol could lead to its conversion to small dense 
LDL particles [19]. Higher level of LDL cholesterol found in males may 
be probably due to stressful life and high incidence of smoking in males. 
Estrogen protects against the risk factors of complications by decreased 
LDL cholesterol and lipoprotein. Estrogen also prevents the oxidation 
of LDL cholesterol. The levels of VLDL were found higher in female 
diabetic patients with microvascular complications, independent of the 
duration of disease.
Diabetic nephropathy and declining kidney function to be associated 
with high level of total cholesterol and triglyceride [20]. Studies have 
shown increased levels of total cholesterol and non-HDL cholesterol 
levels in diabetics and this was found to be associated with increasing 
severity of diabetic retinopathy [21]. Researchers have reported high 
levels of total cholesterol, HDL, and triglycerides in diabetic patients 
and other lipid abnormalities [18,22]. Abnormalities in lipid profile 
might be a result of unbalanced metabolic states of diabetic patients 
that include hyperglycemia and insulin resistance [23]. The variations of 
serum total lipid with sex are different which may be related to dietary 
habits and lifestyle [24]. Studies determined that serum triglycerides 
are more pronounced in females, either with insulin-dependent 
diabetes mellitus (IDDM) or with non-IDDM insulin treated-I than in 
male patients [13,25]. Differences in serum triglycerides may be related 
to a greater adverse effect of diabetes on triglyceride concentration in 
diabetic females than in diabetic males. This may explain the high risk 
of arteriosclerosis in diabetic females. Since, in normal subjects, serum 
triglyceride levels reveal higher values among males than in females, 
normal females usually have less arteriosclerosis vascular disease than 
in males as reported [26-28]. However, no significant difference was 
obtained in the level of serum cholesterol in diabetic and non-diabetic 
subjects in another study [29]. The increase of serum cholesterol 
level in diabetic patients may also be due to increased synthesis of 
cholesterol [30].
There is a clustering of interrelated plasma lipid and lipoprotein 
abnormalities, in diabetic patients and associated with increased 
risk of cardiovascular diseases. Insulin resistance altered metabolism 
of lipids and increased hepatic secretion of VLDL and its impaired 
clearance. Increased hepatic production or reduced clearance from 
plasma of large VLDL also results in increased production of precursors 
of small dense LDL patients. Insulin resistance plays a pivotal role in 
the development of diabetic dyslipidemia by influencing several factors. 















Healthy control (I) 142.85±22.15 132.61±23.97 45.33±12.82 73.32±23.13 26.60±4.76
Diabetic patients without 
microvascular complications (II)
0–5 151.4±20.83 163.4±25.14 40.6±2.12 77.4±17.51 32.68±3.43
5–10 134.45±32.53 133±34.60 41.75±2.54 66.41±20.05 26.58±4.92
Diabetic patients with 
microvascular complications (III)
0–5 173.2±25.74 192±34.26 41.9±3.57 93.04±19.54 38.87±3.40
5–10 139.4±32.17 153.2±32.49 40.9±2.23 65.11±20.76 33.79±2.63
*Data are represented as mean±standard deviation
Table 6: Lipid profile of male diabetic patients with or without microvascular complications













Healthy control (I) 142.6±27.31 121.4±18.11 43.7±1.77 73.48±25.54 25.48±4.21
Diabetic patients without 
microvascular complication (II)
0–5 142.8±16.26 143.4±21.02 41±1.76 73.18±16.69 28.62±4.21
5–10 164.37±18.21 153.75±35.63 38.25±4.13 97.5±15.51 30.75±3.13
Diabetic patients with 
microvascular complications (III)
0–5 161.2±28.39 188.1±32.58 39.9±3.54 83.68±16.84 37.68±4.1
5–10 151±32 152±35.76 40±3.13 84.12±17.14 30.8±3.73
Data are represented as mean±standard deviation
4
Innovare Journal of Health Sciences, Vol 7, Issue 5, 2019, 1-4
 Gill and Kaur 
Increased efflux of free fatty acids from adipose tissue and impaired 
insulin mediated skeletal muscle uptake of free fatty acids increased 
their flux to the liver  [31].
Insulin resistance also increases hepatic lipase activity, which is 
responsible for hydrolysis of phospholipids in LDL and HDL particles 
and leads to smaller and denser LDL particles and decrease in HDL, and 
this ultimately leads to the emergence of complications in the body.
There are various factors which account for gender differences. There 
is a difference in pattern of obesity between males and females. High 
blood sugar levels damaged functional filtering units of kidneys and 
nephrons. As a result, kidneys are unable to maintain the fluid and 
electrolyte homeostasis. It has also been observed that with the 
advancement of age and duration of diabetes disease, renal parameters 
got altered, which indicated renal damage in diabetic patients. Renal 
disease in diabetes is found to be associated with abnormalities of 
vasodilatation and generated reactive oxygen species mediated by 
endothelial-derived nitric oxide, suggesting linkage between vascular 
and metabolic abnormalities. As the disease progresses, albumin leaks 
into urine and filtering function of kidney begins to drop, resulting in 
body’s retention of various wastes [32].
CONCLUSION
It was concluded that the lipid parameters get altered in diabetic 
patients, leading to the dyslipidemia. The cumulative effect of 
hyperglycemia and dyslipidemia leads to the oxidative stress in the 
body. The increased oxidation of lipids may lead to the occurrence 
of microvascular complications in the body. Due to the increased 
prevalence of diabetes in India, funding of this study would suggest that 
there is a need to accelerate the importance of monitoring lipid levels 
in diabetes. Diabetic patients should routinely monitor their glycemic 
status, renal, and lipid profile to avert microvascular complications 
associated with diabetes mellitus.
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